Stoke Therapeutics, Inc. Logo

Stoke Therapeutics, Inc.

Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.

STOK | US

Overview

Corporate Details

ISIN(s):
US86150R1077
LEI:
Country:
United States of America
Address:
45 WIGGINS AVENUE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases. The company's proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), aims to restore normal protein levels by increasing—or "stoking"—protein expression from the healthy copy of a mutated gene. This approach is primarily designed to address haploinsufficiencies, where a single functional gene is insufficient to prevent disease. Stoke's lead candidate, zorevunersen (STK-001), is in clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company's pipeline also includes programs for other genetic disorders, such as autosomal dominant optic atrophy (ADOA).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stoke Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stoke Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stoke Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America
CRVO
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark
CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea
083790
CG Oncology, Inc. Logo
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea
261780

Talk to a Data Expert

Have a question? We'll get back to you promptly.